Search

Your search keyword '"Brugts, J. J."' showing total 129 results
Start Over Author "Brugts, J. J."
129 results on '"Brugts, J. J."'

5. Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial

Author

Clephas, P R D, primary, Zwartkruis, V W, additional, Malgie, J, additional, van Gent, M W F, additional, Brunner-La Rocca, H P, additional, Szymanski, M K, additional, van Halm, V P, additional, Handoko, M L, additional, Kok, W, additional, Asselbergs, F W, additional, van Kimmenade, R, additional, Manintveld, O, additional, van Mieghem, N M D A, additional, Beeres, S L M A, additional, Post, M C, additional, Borleffs, C J W, additional, Tukkie, R, additional, Mosterd, A, additional, Linssen, G C M, additional, Spee, R F, additional, Emans, M E, additional, Smilde, T D J, additional, van Ramshorst, J, additional, Kirchhof, C, additional, Feenema–Aardema, F, additional, da Fonseca, C A, additional, van den Heuve, M, additional, Hazeleger, R, additional, van Eck, M, additional, van Heerebeek, L, additional, Boersma, H, additional, Rienstra, M, additional, de Boer, R A, additional, and Brugts, J J, additional

Published
2024
Full Text
View/download PDF

6. The plasma proteome is linked with left ventricular and left atrial function parameters in patients with chronic heart failure

Author

Abou Kamar, S, primary, Andrzejczyk, K, additional, Petersen, T B, additional, Chin, J F, additional, Aga, Y S, additional, de Bakker, M, additional, Akkerhuis, K M, additional, Geleijnse, M, additional, Brugts, J J, additional, Sorop, O, additional, de Boer, R A, additional, Rizopoulos, D, additional, Asselbergs, F W, additional, Boersma, E, additional, den Ruijter, H, additional, van Dalen, B M, additional, and Kardys, I, additional

Published
2024
Full Text
View/download PDF

8. The plasma proteome is linked with left ventricular and left atrial function parameters in patients with chronic heart failure.

Author

Kamar, S Abou, Andrzejczyk, K, Petersen, T B, Chin, J F, Aga, Y S, Bakker, M de, Akkerhuis, K M, Geleijnse, M, Brugts, J J, Sorop, O, Boer, R A de, Rizopoulos, D, Asselbergs, F W, Boersma, E, Ruijter, H den, Dalen, B M van, and Kardys, I

Subjects
LEFT heart ventricle, PROTEINS, LEFT heart atrium, VENTRICULAR ejection fraction, RESEARCH funding, BLOOD proteins, HEART failure, DESCRIPTIVE statistics, CHRONIC diseases, LONGITUDINAL method, GENE expression, CYSTATINS, PROTEOMICS, COLLECTION & preservation of biological specimens, ECHOCARDIOGRAPHY
Abstract

Aims Examining the systemic biological processes in the heterogeneous syndrome of heart failure with reduced ejection fraction (HFrEF), as reflected by circulating proteins, in relation to echocardiographic characteristics, may provide insights into heart failure pathophysiology. We investigated the link of 4210 repeatedly measured circulating proteins with repeatedly measured echocardiographic parameters as well as with elevated left atrial pressure (LAP), in patients with HFrEF, to provide insights into underlying mechanisms. Methods and results In 173 patients with HFrEF, we performed 6-monthly echocardiography and trimonthly blood sampling during a median follow-up of 2.7 (inter-quartile range: 2.5–2.8) years. We investigated circulating proteins in relation to echocardiographic parameters of left ventricular [left ventricular ejection fraction (LVEF), global longitudinal strain (GLS)] and left atrial function [left atrial reservoir strain (LASr)] and elevated LAP (E / e ʹ ratio >15) and used gene enrichment analyses to identify underlying pathophysiological processes. We found 723, 249, 792, and 427 repeatedly measured proteins, with significant associations with LVEF, GLS, LASr, and E / e ʹ ratio, respectively. Proteins associated with LASr reflected pathophysiological mechanisms mostly related to the extracellular matrix. Proteins associated with GLS reflected cardiovascular biological processes and diseases, whereas those associated with LVEF reflected processes involved in the sympathetic nervous system. Moreover, 49 proteins were associated with elevated LAP; after correction for LVEF, three proteins remained: cystatin-D, fibulin-5, and HSP40. Conclusion Circulating proteins show varying associations with different echocardiographic parameters in patients with HFrEF. These findings suggest that pathways involved in atrial and ventricular dysfunction, as reflected by the plasma proteome, are distinct. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure: Design and rationale of the MONITOR HF multicentre randomised clinical trial

Author

Brugts, J. J., Veenis, J. F., Radhoe, S. P., Linssen, G. C. M., van Gent, M., Borleffs, C. J. W., van Ramshorst, J., van Pol, P., Tukkie, R., Spee, R. F., Emans, M. E., Kok, W., van Halm, V., Handoko, L., Beeres, S. L. M. A., Post, M. C., Boersma, E., Lenzen, M. J., Manintveld, O. C., Koffijberg, H., van Baal, P., Versteegh, M., Smilde, T. D., van Heerebeek, L., Rienstra, M., Mosterd, A., Delnoy, P. P. H., Asselbergs, F. W., Brunner-La Rocca, H. P., and de Boer, R. A.

Published
2020
Full Text
View/download PDF

24. A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure

Author

Brugts, J. J., Veenis, J. F., Radhoe, S. P., Linssen, G. C. M., van Gent, M., Borleffs, C. J. W., van Ramshorst, J., van Pol, P., Tukkie, R., Spee, R. F., Emans, M. E., Kok, W., van Halm, V., Handoko, L., Beeres, S. L. M. A., Post, M. C., Boersma, E., Lenzen, M. J., Manintveld, O. C., Koffijberg, H., van Baal, P., Versteegh, M., Smilde, T. D., van Heerebeek, L., Rienstra, M., Mosterd, A., Delnoy, P. P. H., Asselbergs, F. W., Brunner-La Rocca, H. P., and de Boer, R. A.

Subjects
Telemonitoring, e‑Health, CardioMEMS, Heart failure, Therapy, Original Article – Design Study Article, Trial
Abstract

Background Assessing haemodynamic congestion based on filling pressures instead of clinical congestion can be a way to further improve quality of life (QoL) and clinical outcome by intervening before symptoms or weight gain occur in heart failure (HF) patients. The clinical efficacy of remote monitoring of pulmonary artery (PA) pressures (CardioMEMS; Abbott Inc., Atlanta, GA, USA) has been demonstrated in the USA. Currently, the PA sensor is not reimbursed in the European Union as its benefit when applied in addition to standard HF care is unknown in Western European countries, including the Netherlands. Aims To demonstrate the efficacy and cost-effectiveness of haemodynamic PA monitoring in addition to contemporary standard HF care in a high-quality Western European health care system. Methods The current study is a prospective, multi-centre, randomised clinical trial in 340 patients with chronic HF (New York Heart Association functional class III) randomised to HF care including remote monitoring with the CardioMEMS PA sensor or standard HF care alone. Eligible patients have at least one hospitalisation for HF in 12 months before enrolment and will be randomised in a 1:1 ratio. Minimum follow-up will be 1 year. The primary endpoint is the change in QoL as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Secondary endpoints are the number of HF hospital admissions and changes in health status assessed by EQ-5D-5L questionnaire including health care utilisation and formal cost-effectiveness analysis. Conclusion The MONITOR HF trial will evaluate the efficacy and cost-effectiveness of haemodynamic monitoring by CardioMEMS in addition to standard HF care in patients with chronic HF. Clinical Trial Registration number NTR7672. Electronic supplementary material The online version of this article (10.1007/s12471-019-01341-9) contains supplementary material, which is available to authorized users.

Published
2019

26. Endovascular renal sympathetic denervation to improve heart failure with reduced ejection fraction: the IMPROVE-HF-I study

Author

Feyz, L., primary, Nannan Panday, R., additional, Henneman, M., additional, Verzijlbergen, F., additional, Constantinescu, A. A., additional, van Dalen, B. M., additional, Brugts, J. J., additional, Caliskan, K., additional, Geleijnse, M. L., additional, Kardys, I., additional, Van Mieghem, N. M., additional, Manintveld, O., additional, and Daemen, J., additional

Published
2021
Full Text
View/download PDF

37. P1675Evolution of lactate dehydrogenase levels in patients with HeartMate II, HeartWare and HeartMate 3 left ventricular assist devices during first-year follow-up

Author

Yalcin, Y C, primary, Muslem, R, additional, Papageorgiou, G, additional, Tedford, R J, additional, Constantinescu, A A, additional, Birim, O C, additional, Brugts, J J, additional, Manintveld, O C, additional, Hsu, S, additional, Leebeek, F W G, additional, Bogers, A J J C, additional, and Caliskan, K, additional

Published
2019
Full Text
View/download PDF

38. 2178Survival differences of left ventricle assist device carriers according to implantation eras - results from the European PCHF-VAD registry

Author

Jakus, N, primary, Brugts, J J, additional, Timmermans, P, additional, Pouleur, A C, additional, Rubis, P, additional, Van Craenenbroeck, E, additional, Gaizauskas, E, additional, Grundmann, S, additional, Paolillo, S, additional, Barge-Caballero, E, additional, D'Amario, D, additional, Gkouziouta, A, additional, Milicic, D, additional, Ruschitzka, F, additional, and Cikes, M, additional

Published
2019
Full Text
View/download PDF

42. Differences in guideline-recommended heart failure medication between Dutch heart failure clinics: an analysis of the CHECK-HF registry.

Author

Linssen, G. C. M., Veenis, J. F., Brunner-La Rocca, H. P., van Pol, P. E. J., Engelen, D. J. M., van Tooren, R. M., Koornstra-Wortel, H. J. J., Hoes, A. W., and Brugts, J. J.

Subjects
HEART failure, GLOMERULAR filtration rate, MINERALOCORTICOID receptors, RENIN-angiotensin system, OUTPATIENT medical care
Abstract

Background: Heart failure (HF) is associated with poor prognosis, high morbidity and mortality. The prognosis can be optimised by guideline adherence, which also can be used as a benchmark of quality of care. The purpose of this study was to evaluate differences in use of HF medication between Dutch HF clinics. Methods: The current analysis was part of a cross-sectional registry of 10,910 chronic HF patients at 34 Dutch outpatient clinics in the period of 2013 until 2016 (CHECK-HF), and focused on the differences in prescription rates between the participating clinics in patients with heart failure with reduced ejection fraction (HFrEF). Results: A total of 8,360 HFrEF patients were included with a mean age of 72.3 ± 11.8 years (ranging between 69.1 ± 11.9 and 76.6 ± 10.0 between the clinics), 63.9% were men (ranging between 54.3 and 78.1%), 27.3% were in New York Heart Association (NYHA) class III/IV (ranging between 8.8 and 62.1%) and the average estimated glomerular filtration rate (eGFR) was 59.6 ± 24.6 ml/min (ranging between 45.7 ± 23.5 and 97.1 ± 16.5). The prescription rates ranged from 58.9–97.4% for beta blockers (p < 0.01), 61.9–97.1% for renin-angiotensin system (RAS) inhibitors (p < 0.01), 29.9–86.8% for mineralocorticoid receptor antagonists (MRAs) (p < 0.01), 0.0–31.3% for ivabradine (p < 0.01) and 64.9–100.0% for diuretics (p < 0.01). Also, the percentage of patients who received the target dose differed significantly, 5.9–29.1% for beta blockers (p < 0.01), 18.4–56.1% for RAS inhibitors (p < 0.01) and 13.2–60.6% for MRAs (p < 0.01). Conclusions: The prescription rates and prescribed dosages of guideline-recommended medication differed significantly between HF outpatient clinics in the Netherlands, not fully explained by differences in patient profiles. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

48. Remote monitoring of pulmonary artery pressures with CardioMEMS in patients with chronic heart failure and NYHA class III: first experiences in the Netherlands.

Author

Brugts, J. J., Manintveld, O. C., and van Mieghem, N.

Subjects
CLINICAL trials, HEART failure, PULMONARY artery, HOSPITAL admission & discharge, MEDICAL care of cardiac patients
Abstract

We report the first patient experiences with the CardioMEMS device in the Erasmus MC Thorax Center in the Netherlands. In line with clinical trial evidence, the device is applicable in patients with chronic heart failure in functional New York Heart Association class III with at least 1 admission for heart failure in the past 12 months. CardioMEMS has been shown to be safe and reliable, and effective in reducing the number of hospitalisations for heart failure by guided therapy based on pulmonary artery pressures. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

50. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials

Author

Brugts, J. J., primary, Ninomiya, T., additional, Boersma, E., additional, Remme, W. J., additional, Bertrand, M., additional, Ferrari, R., additional, Fox, K., additional, MacMahon, S., additional, Chalmers, J., additional, and Simoons, M. L., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results